A5007560083- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Organ Transplantation Techniques and Outcomes
- Inflammatory Bowel Disease
- Liver Diseases and Immunity
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Gastrointestinal Bleeding Diagnosis and Treatment
- Gastrointestinal disorders and treatments
- Clinical Nutrition and Gastroenterology
- Microscopic Colitis
- Hepatocellular Carcinoma Treatment and Prognosis
- Eosinophilic Esophagitis
- Hepatitis Viruses Studies and Epidemiology
- Autoimmune and Inflammatory Disorders
- Pancreatitis Pathology and Treatment
- Nutrition and Health in Aging
- Drug-Induced Hepatotoxicity and Protection
- Renal Transplantation Outcomes and Treatments
- Diagnosis and treatment of tuberculosis
- Gastrointestinal Tumor Research and Treatment
- Alcohol Consumption and Health Effects
- Systemic Lupus Erythematosus Research
- Mycobacterium research and diagnosis
- Pneumocystis jirovecii pneumonia detection and treatment
University Hospital of Bern
2017-2025
University of Bern
2017-2025
Hospital Garcia de Orta
2022-2024
Hospital de São João
2014-2023
University of Coimbra
2023
Universidade do Porto
2010-2020
Centro Hospitalar de Vila Nova de Gaia
2019
Maastricht University
2018
Hospital Curry Cabral
2014-2017
Centro Hospitalar de Lisboa Central
2017
Abstract Background Although malnutrition and sarcopenia are prevalent in cirrhosis, their impact on outcomes following liver transplantation is not well documented. Methods The associations of nutritional status with post‐transplant infections, requirement for mechanical ventilation, intensive care (ICU) hospital stay, 1 year mortality were assessed 232 consecutive transplant recipients. Nutritional using the Royal Free Hospital‐Global Assessment (RFH‐GA) tool L3‐psoas muscle index (L3‐PMI)...
Patients admitted with acute variceal bleeding (AVB) and Child-Pugh C score (CP-C) or B plus active at endoscopy (CP-B+AB) are high risk for treatment failure, rebleeding, mortality. A preemptive transjugular intrahepatic portosystemic shunt (p-TIPS) has been shown to improve survival in these patients, but its use clinical practice challenged not routinely incorporated. The present study aimed further validate the role of TIPS a large number high-risk patients. This multicenter,...
INTRODUCTION: We aimed to explore the prevalence of portal hypertension in most common etiologies patients with compensated advanced chronic liver disease (cACLD) and develop classification rules, based on stiffness measurement (LSM), that could be readily used diagnose or exclude clinically significant (CSPH) clinical practice. METHODS: This is an international cohort study including paired LSM/hepatic venous pressure gradient (HVPG), LSM ≥10 kPa, no previous decompensation. Portal was...
•Variceal bleeding is frequently associated with ACLF in cirrhosis.•ACLF independently rebleeding and mortality.•Patients variceal can benefit from a pre-emptive (early) TIPS. Background & AimsThe relationship between acute-on-chronic liver failure (ACLF) acute (AVB) poorly understood. Specifically, the prevalence prognosis of context AVB unclear, while role transjugular intrahepatic portosystemic shunt (TIPS) management patients has not been described to date.MethodsA multicenter,...
This article describes cases of anti-tumor necrosis factor (TNF)-α-induced autoimmune hepatitis and evaluates the outcome these patients in relation to their immunosuppressive strategy.A retrospective analysis medical records was performed our center, order detect (AIH) associated with anti-TNF biologic agents.We describe analyze eight AIH following therapy, 7 infliximab 1 adalimumab.A distinction should be made between induction autoimmunity clinically evident disease.Liver biopsy is useful...
A pre-emptive transjugular intrahepatic portosystemic shunt (pTIPS) reduces mortality in high-risk patients with cirrhosis (Child-Pugh C/B+active bleeding) acute variceal bleeding (AVB). Real-life studies point out that <15% of eligible for pTIPS ultimately undergo (TIPS) due to concerns about hepatic encephalopathy (HE). The outcome undergoing HE is unknown. We aimed (1) assess the prevalence AVB; (2) evaluate presenting at admission after pTIPS; and (3) determine if a risk factor death...
Immunization against hepatitis B virus (HBV) infection is recommended in patients with inflammatory bowel disease (IBD), particularly those under immunosuppressive therapy. Limited data are available about IBD patient's response to HBV vaccination. We assessed the rate vaccination and evaluated impact of different factors on efficacy vaccination.Anti-HBs titers were measured a cohort treatment infliximab and/or azathioprine. Vaccination was considered efficient when anti-HBs higher than 10...
A evolução dos recursos eletrônicos no ensino iniciou com computadores e projetores, progrediu para plataformas online aplicativos, hoje inclui realidade virtual aumentada. mudança envolveu a adaptação de métodos tradicionais, chegada programas simulação materiais didáticos digitais. As ferramentas digitais aprimoram o ao tornar conceitos abstratos mais acessíveis por meio simulações ambientes virtuais. Apesar das vantagens, ambiente digital traz desafios, como sobrecarga informações, dados...
Cereulide and valinomycin are highly similar cyclic dodecadepsipeptides with potassium ionophoric properties. Cereulide, produced by members of the Bacillus cereus group, is known mostly as emetic toxin, no ecological function has been assigned. A comparative analysis antimicrobial activity Streptomyces spp. cereulide was performed at a pH range 5.5 to 9.5, under anaerobic aerobic conditions. Both compounds display pH-dependent against selected Gram-positive bacteria, including...
Histological healing has emerged as a promising therapeutic goal in ulcerative colitis. This is especially important the context of biological therapies. The objectives present study were to investigate ability infliximab induce histological remission colitis [UC] patients and explore utility faecal calprotectin lactoferrin predicting activity. Multi-centre, single-cohort, open-label, 52-week trial including moderately severely biological-naïve UC receiving intravenous [5mg/kg]. primary...